Anti-Neurocan antibody, Mouse monoclonal

Description

• General description: Monoclonal Anti-Neurocan (mouse IgG1 isotype) is derived from the hybridoma 650.24 produced by the fusion of mouse myeloma cells (P3X cells) and splenocytes from BALB/c mice immunized with embryonic rat brain proteoglycans. Neurocan is a chondroitin sulfate proteoglycan (known also as CSPG3). It accounts for 20−30% of chondroitin sulfate proteoglycans in early postnatal rat brain. The mouse neurocan cDNA encodes for a 1,257-amino acid protein with a 22-amino acid signal peptide followed by an immunoglobulin-like domain and repeating motifs characteristic of the hyaluronic acid-binding region of aggregating proteoglycans. Neurocan is found in large amounts in glial scar, a primarily astrocytic structure formed after an injury in the central nervous system (CNS).
• Immunogen: embryonic rat brain proteoglycans.
• Application: Anti-Neurocan antibody, Mouse monoclonal has been used in:western blottingimmunofluorescenceenzyme-linked immunosorbent assay (ELISA) immunocytochemistryimmunohistochemistry
• Biochem/physiol Actions: Neurocan can inhibit the growth of axons. In presence of central nervous system injuries, it also takes part in tissue repair and neural network reconstruction.
• Target description: Neurocan is a chondroitin sulfate proteoglycan (knownalso as CSPG3) thought to be involved in the modulation of cell adhesion and migration. It accounts for 20-30% of chondroitin sulfate proteoglycans in early postnatal rat brain.
• Physical form: Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.